Modulation of Human CYP19A1 Activity by Mutant NADPH P450 Oxidoreductase
The DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index.
Abstract
Mutations in NADPH P450 oxidoreductase (POR) cause a broad spectrum of human disease with abnormalities in steroidogenesis. We have studied the impact of P450 reductase mutations on the activity of CYP19A1. POR supported CYP19A1 activity with a calculated Km of 126 nm for androstenedione and a Vmax of 1.7 pmol/min. Mutations R457H and V492E located in the FAD domain of POR that disrupt electron transfer caused a complete loss of CYP19A1 activity. The A287P mutation of POR decreased the activities of CYP17A1 by 60-80% but had normal CYP19A1 activity. Molecular modeling and protein docking studies suggested that A287P is involved in the interaction of POR:CYP17A1 but not in the POR:CYP19A1 interaction. Mutations C569Y and V608F in the NADPH binding domain of POR had 49 and 28% of activity of CYP19A1 compared with normal reductase and were more sensitive to the amount of NADPH available for supporting CYP19A1 activity. Substitution of NADH for NADPH had a higher impact on C569Y and V608F mutants of POR. Similar effects were obtained at low/high (5.5/8.5) pH, but using octanol to limit the flux of electrons from POR to CYP19A1 inhibited activity supported by all variants. High molar ratios of KCl also reduced the CYP19A1 supporting activities of C569Y and V608F mutants of POR to a greater extent compared to normal POR and A287P mutant. Because POR supports many P450s involved in steroidogenesis, bone formation, and drug metabolism, variations in the effects of POR mutations on specific enzyme activities may explain the broad clinical spectrum of POR deficiency.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, a previous in vitro study found that p.A287P does not impair CYP19A1 activity, but p.R457H abolishes aromatase activity (29).”
From Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency (2012) · cites this paper as [29]
In the citing paper
“Together, these findings strongly suggest that p.R457H is a common pathogenic variant in East Asian populations.”
From Case Report: Integrating clinical presentation and genetic analysis in P450 oxidoreductase deficiency: a novel mutation and systematic review (2026) · cites this paper as [68]
In the citing paper
“Not surprisingly, the R457H mutant cannot support P450aro activity in vitro, whereas the A287P mutant retains full activity with P450aro (328).”
From The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders (2011) · cites this paper as [328]
Citations
Cites
Comparative Protein Modelling by Satisfaction of Spatial Restraints
Šali, A., & Blundell, T. L. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1626 · Cited by 12,977
SWISS‐MODEL and the Swiss‐Pdb Viewer: An environment for comparative protein modeling
Guex, N., & Peitsch, M. C. (1997) · ELECTROPHORESIS · doi:10.1002/elps.1150181505 · Cited by 11,241
Multiple sequence alignment with the Clustal series of programs
Chenna, R. (2003) · Nucleic Acids Research · doi:10.1093/nar/gkg500 · Cited by 4,875
Stereochemistry of polypeptide chain configurations
Ramachandran, G. N., Ramakrishnan, C., & Sasisekharan, V. (1963) · Journal of Molecular Biology · doi:10.1016/s0022-2836(63)80023-6 · Cited by 3,554
WHAT IF: A molecular modeling and drug design program
Vriend, G. (1990) · Journal of Molecular Graphics · doi:10.1016/0263-7855(90)80070-v · Cited by 3,469
[20] VERIFY3D: Assessment of protein models with three-dimensional profiles
Eisenberg, D., Lüthy, R., & Bowie, J. U. (1997) · Methods in Enzymology · doi:10.1016/s0076-6879(97)77022-8 · Cited by 2,192
Hooft, R. W. W., Vriend, G., Sander, C., & Abola, E. E. (1996) · Nature · doi:10.1038/381272a0 · Cited by 2,173
Stereochemical quality of protein structure coordinates
Morris, A. L., MacArthur, M. W., Hutchinson, E. G., & Thornton, J. M. (1992) · Proteins: Structure, Function, and Bioinformatics · doi:10.1002/prot.340120407 · Cited by 1,553
Phillips, A. H., & Langdon, R. G. (1962) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)73803-4 · Cited by 1,427
Molecular biology of steroid hormone synthesis
MILLER, W. L. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-3-295 · Cited by 1,397
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
NADPH P450 oxidoreductase: Structure, function, and pathology of diseases
Pandey, A. V., & Flück, C. E. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.010 · Cited by 279
Self-citationFlück, C. E., Meyer-Böni, M., Pandey, A. V., Kempná, P., Miller, W. L., Schoenle, E. J., & Biason-Lauber, A. (2011) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2011.06.009 · Cited by 248
Self-citationSteroidogenesis: Unanswered Questions
Miller, W. L. (2017) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2017.09.002 · Cited by 226
Huang, N., Agrawal, V., Giacomini, K. M., & Miller, W. L. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711621105 · Cited by 198
Alternative (backdoor) androgen production and masculinization in the human fetus
O’Shaughnessy, P. J., Antignac, J. P., Le Bizec, B., Morvan, M.-L., Svechnikov, K., Söder, O., Savchuk, I., Monteiro, A., Soffientini, U., Johnston, Z. C., et al. (2019) · PLOS Biology · doi:10.1371/journal.pbio.3000002 · Cited by 177
Genotype-Phenotype Analysis in Congenital Adrenal Hyperplasia due to P450 Oxidoreductase Deficiency
Krone, N., Reisch, N., Idkowiak, J., Dhir, V., Ivison, H. E., Hughes, B. A., Rose, I. T., O'Neil, D. M., Vijzelaar, R., Smith, M. J., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0640 · Cited by 163
NADPH–Cytochrome P450 Oxidoreductase: Roles in Physiology, Pharmacology, and Toxicology
Riddick, D. S., Ding, X., Wolf, C. R., Porter, T. D., Pandey, A. V., Zhang, Q., Gu, J., Finn, R. D., Ronseaux, S., McLaughlin, L. A., et al. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048991 · Cited by 164
“The severity of aromatase inhibition by P399_E401del (;85%) and in utero virilization may be linked as we have suggested earlier for other mutations in the NADPH-binding domain of POR (Pandey et al., 2007).”
BackgroundMethodSelf-citationGilep, A. A., Sushko, T. A., & Usanov, S. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.06.021 · Cited by 145
MECHANISMS IN ENDOCRINOLOGY: Rare defects in adrenal steroidogenesis
Miller, W. L. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0279 · Cited by 136
Aromatase deficiency in men: a clinical perspective
Rochira, V., & Carani, C. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.176 · Cited by 134
“Furthermore, the possible role of aromatase enzyme impairment in combined dysfunction of the enzymatic pathways of steroidogenesis should be taken into account”
BackgroundGomes, A. M., Winter, S., Klein, K., Turpeinen, M., Schaeffeler, E., Schwab, M., & Zanger, U. M. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.7 · Cited by 125
Mutations in the mitochondrial thioredoxin reductase gene TXNRD2 cause dilated cardiomyopathy
Sibbing, D., Pfeufer, A., Perisic, T., Mannes, A. M., Fritz‐Wolf, K., Unwin, S., Sinner, M. F., Gieger, C., Gloeckner, C. J., Wichmann, H. ‐., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehq507 · Cited by 120
Fukami, M., Nishimura, G., Homma, K., Nagai, T., Hanaki, K., Uematsu, A., Ishii, T., Numakura, C., Sawada, H., Nakacho, M., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2816 · Cited by 117
“enzymes would have a certain role (5, 11, 12).”
BackgroundAgrawal, V., Huang, N., & Miller, W. L. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32830054ac · Cited by 117
NADPH–cytochrome P450 oxidoreductase: Prototypic member of the diflavin reductase family
Iyanagi, T., Xia, C., & Kim, J.-J. P. (2012) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2012.09.002 · Cited by 117
Fukami, M., Homma, K., Hasegawa, T., & Ogata, T. (2013) · Developmental Dynamics · doi:10.1002/dvdy.23892 · Cited by 114
“…although the p.A287P mutation, which is frequent in Caucasian patients with PORD (Miller, 2004; Scott and Miller, 2008), provides grossly normal supporting activities for CYP19A1 (Pandey et al., 2007), virilization has been reported in some females with this mutation (Huang et al., 2005).”
BackgroundInfluentialPlasticity of specialized metabolism as mediated by dynamic metabolons
Laursen, T., Møller, B. L., & Bassard, J.-É. (2014) · Trends in Plant Science · doi:10.1016/j.tplants.2014.11.002 · Cited by 120
Agrawal, V., Choi, J. H., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833e0cb5 · Cited by 104
Zhu, F., Sams, S., Moural, T. W., Haynes, K. F., Potter, M. F., & Palli, S. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031037 · Cited by 115
“As an obligatory electron donor, CPR transfers electrons from NADPH to various cytochrome P450s that play central roles in detoxification of xenobiotics [41].”
InfluentialPharmacogenomics of human P450 oxidoreductase
Pandey, A. V., & Sproll, P. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00103 · Cited by 92
“Data were compiled from previous reports (Flück et al., 2004, 2010, 2011a; Pandey et al., 2004, 2007, 2010; Huang et al., 2005, 2008; Agrawal et al., 2008, 2010; Nicolo et al., 2010; Sandee et al., 2010).”
BackgroundInfluentialSelf-citationExtraadrenal 21-Hydroxylation by CYP2C19 and CYP3A4: Effect on 21-Hydroxylase Deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1174 · Cited by 91
“This variability is consistent with other studies showing that the activity of a POR variant with one P450 enzyme will not predict its activity with another P450 (24, 39).”
Methodvon Wolff, M., Kollmann, Z., Flück, C. E., Stute, P., Marti, U., Weiss, B., & Bersinger, N. A. (2014) · Human Reproduction · doi:10.1093/humrep/deu044 · Cited by 94
“Aromatase activity measurements were then performed by the tritiated water release assay as described elsewhere (Lephart and Simpson, 1991; Pandey et al., 2007) on this material.”
MethodSelf-citationConsequences of POR mutations and polymorphisms
Miller, W. L., Agrawal, V., Sandee, D., Tee, M. K., Huang, N., Choi, J. H., Morrissey, K., & Giacomini, K. M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.10.022 · Cited by 88
“First, there is partial deficiency placental aromatase (P450aro) activity in some, but not all, pregnancies (Fluck et al., 2004; Huang et al., 2005), resulting in fetal virilization similar to that seen with P450aro deficiency.”
BackgroundInfluentialClinical, genetic and enzymatic characterization of P450 oxidoreductase deficiency in four patients
Sahakitrungruang, T., Huang, N., Tee, M. K., Agrawal, V., Russell, W. E., Crock, P., Murphy, N., Migeon, C. J., & Miller, W. L. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1460 · Cited by 82
P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms
Burkhard, F. Z., Parween, S., Udhane, S. S., Flück, C. E., & Pandey, A. V. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.04.003 · Cited by 79
“Both C569Y and V608F caused a greater reduction in the activity of CYP19A1 compared to their effects on activities of CYP17A1 [6,12,14].”
BackgroundMethodResultInfluentialSelf-citationTomalik-Scharte, D., Maiter, D., Kirchheiner, J., Ivison, H. E., Fuhr, U., & Arlt, W. (2010) · European Journal of Endocrinology · doi:10.1530/eje-10-0764 · Cited by 77
Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro
Sandee, D., Morrissey, K., Agrawal, V., Tam, H. K., Kramer, M. A., Tracy, T. S., Giacomini, K. M., & Miller, W. L. (2010) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e32833f4f9b · Cited by 74
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic Pathway
Castaño, P. R., Parween, S., & Pandey, A. V. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184606 · Cited by 72
“From each reaction, 500 μL aliquots were taken for the measurement of radioactivity by scintillation counting using the Rotiszint Universal Cocktail (Carl Roth GmbH, Karlsruhe, Germany), and aromatase activity was calculated as described previously [93,94].”
MethodSelf-citationShi, L., Zhang, J., Shen, G., Xu, Z., Peng, W., Zhang, Y., Xu, Q., & He, L. (2015) · Scientific Reports · doi:10.1038/srep15581 · Cited by 77
Prenatal diagnosis of congenital adrenal hyperplasia caused by P450 oxidoreductase deficiency
Reisch, N., Idkowiak, J., Hughes, B. A., Ivison, H. E., Abdul-Rahman, O. A., Hendon, L. G., Olney, A. H., Nielsen, S., Harrison, R., Blair, E. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3449 · Cited by 67
“Finally, CYP19A1 aromatase activity itself could be impaired by mutant POR, further contributing to low estriol production, which again could show some variability in PORD with distinct mutants having been shown to have a differential impact on aromatase activity in vitro (15).”
Bouchoucha, N., Samara‐Boustani, D., Pandey, A. V., Bony-Trifunovic, H., Hofer, G., Aigrain, Y. Y., Polak, M., & Flück, C. E. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.03.008 · Cited by 69
“The molecular dynamics simulations were performed using AMBER03 force field as described in earlier publications (Pandey et al., 2007; Krieger et al., 2004; Flück et al., 2009, 2011).”
MethodInfluentialSelf-citationFlück, C. E., Mullis, P. E., & Pandey, A. V. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.09.035 · Cited by 59
“compiled from published studies on effects of POR variants [8,11,14,19,25].”
BackgroundInfluentialSelf-citationBaronio, F., Ortolano, R., Menabò, S., Cassio, A., Baldazzi, L., Natale, V. D., Tonti, G., Vestrucci, B., & Balsamo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184605 · Cited by 60
P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia
Flück, C. E., & Miller, W. L. (2006) · Current Opinion in Pediatrics · doi:10.1097/01.mop.0000236395.71956.5c · Cited by 57
Self-citationFukami, M., & Ogata, T. (2014) · Pediatrics International · doi:10.1111/ped.12518 · Cited by 56
The common P450 oxidoreductase variant A503V is not a modifier gene for 21-hydroxylase deficiency
Gomes, L. G., Huang, N., Agrawal, V., Mendonça, B. B., Bachega, T. A. S. S., & Miller, W. L. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0304 · Cited by 52
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Brook's Clinical Pediatric Endocrinology · doi:10.1002/9781444316728.ch13 · Cited by 50
Clinical and Biochemical Consequences of P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2011) · Endocrine Development · doi:10.1159/000321221 · Cited by 52
Self-citationKranendonk, M., Marohnic, C. C., Panda, S. P., Duarte, M. P., Oliveira, J. S., Masters, B. S. S., & Rueff, J. (2008) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2008.04.014 · Cited by 60
Restoration of mutant cytochrome P450 reductase activity by external flavin
Nicolo, C., Flück, C. E., Mullis, P. E., & Pandey, A. V. (2010) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2010.02.024 · Cited by 50
Self-citationSpecificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
Udhane, S. S., Dick, B., Hu, Q., Hartmann, R. W., & Pandey, A. V. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.019 · Cited by 46
Self-citationMutations and Polymorphisms in the HumanArgininosuccinate Lyase(ASL) Gene
Balmer, C., Pandey, A. V., Rüfenacht, V., Nuoffer, J., Fang, P., Wong, L. C., & Häberle, J. (2013) · Human Mutation · doi:10.1002/humu.22469 · Cited by 52
“…and hydrogen bonds, changes in charge, size and volume of the altered amino acid, and interaction with neighboring residues, to evaluate the impact of mutations as described previously for several other proteins and structures [Flück et al., 2009; Pandey et al., 2007; Pandey and Mullis, 2011].”
BackgroundSelf-citationChen, X., Pan, L. Q., Naranmandura, H., Zeng, S., & Chen, S. Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038495 · Cited by 53
Fernández‐Cancio, M., Camats, N., Flück, C. E., Zalewski, A., Dick, B., Frey, B. M., Monné, R., Torán, N., Audí, L., & Pandey, A. V. (2018) · Pharmaceuticals · doi:10.3390/ph11020037 · Cited by 50
Self-citationHuang, Y., Liao, M., Yang, Q., Shi, S., Xiao, J., & Cao, H. (2019) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2019.07.008 · Cited by 48
Subramanian, M., Agrawal, V., Sandee, D., Tam, H. K., Miller, W. L., & Tracy, T. S. (2012) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3283544062 · Cited by 43
Diagnosis and Treatment of Disorders of Sexual Development
Rey, R. A., & Josso, N. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00119-0 · Cited by 40
Flück, C. E., Mallet, D., Hofer, G., Samara‐Boustani, D., Léger, J., Polak, M., Morel, Y., & Pandey, A. V. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.08.001 · Cited by 43
“The activity of CYP19A1 was assayed by the release of tritiated water from 1b-(3)H substrates during aromatization as described [26].”
BackgroundMethodSelf-citationImpact on CYP19A1 activity by mutations in NADPH cytochrome P450 oxidoreductase
Flück, C. E., & Pandey, A. V. (2016) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.03.031 · Cited by 43
“Many variations in the POR that have been identified from genetic analysis of patients as well as from genome sequencing studies have been tested in several enzyme assays [10,12,27,28].”
InfluentialSelf-citationParween, S., DiNardo, G., Baj, F., Zhang, C., Gilardi, G., & Pandey, A. V. (2020) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105507 · Cited by 39
Self-citationHuang, Y., Lu, X., Wang, L., Wei, D., Feng, Z.-J., Zhang, Q., Xiao, L., Dou, W., & Wang, J. (2015) · Scientific Reports · doi:10.1038/srep18394 · Cited by 42
Udhane, S. S., Parween, S., Kagawa, N., & Pandey, A. V. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00580 · Cited by 38
“Aromatase activity was measured by the tritiated water release assay originally described by Lephart and Simpson (1991) with modifications as described by us previously (Pandey et al., 2007; Flück and Pandey, 2017) using a reconstituted lipid-CYP19A1-POR system and androstenedione as the substrate.”
BackgroundMethodInfluentialSelf-citationParween, S., Roucher-Boulez, F., Flück, C. E., Lienhardt-Roussie, A., Mallet, D., Morel, Y., & Pandey, A. V. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1928 · Cited by 37
“The molecular dynamics simulations were performed using AMBER03 force field (15, 21).”
BackgroundMethodInfluentialSelf-citationZhang, Y., Wang, Y., Wang, L., Yao, J., Guo, H., & Fang, J. (2015) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2015.08.006 · Cited by 41
Pandey, A. V., Flück, C. E., & Mullis, P. E. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.08.072 · Cited by 36
Self-citationFinding New Molecular Targets of Familiar Natural Products Using In Silico Target Prediction
Mayr, F., Möller, G., Garscha, U., Fischer, J., Castaño, P. R., Inderbinen, S. G., Temml, V., Waltenberger, B., Schwaiger, S., Hartmann, R. W., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197102 · Cited by 46
“Aromatase assays were performed as previously described [70].”
MethodSelf-citationMicrosomal cytochrome P450 as a target for drug discovery and repurposing
El-Sherbeni, A. A., & El‐Kadi, A. O. S. (2016) · Drug Metabolism Reviews · doi:10.1080/03602532.2016.1257021 · Cited by 36
“…Dubrac et al., 2005; Inoue et al., 2006; Ioannides, 2008; Karlgren et al., 2006; Midzak et al., 2011; Mizrachi et al., 2011; Pandak et al., 2002; Pandey et al., 2007; Ruan et al., 1994; Schwarz et al., 1999; Shinkyo et al., 2004; Slavotinek et al., 2013; Tripathy et al., 2016; Ullrich et al.,…”
BackgroundWang, K., Peng, X., Zuo, Y., Li, Y., & Chen, M. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154633 · Cited by 35
“Due to this hydrophobic segment, the remainder of CPR likely faces the cytoplasmic side of the membrane of the ER [45,46], which is important for electron transfer.”
BackgroundCytochrome P450 Oxidoreductase Deficiency
Idkowiak, J., Cragun, D. L., Hopkin, R. J., & Arlt, W. (2009) · University of Washington, Seattle eBooks · Cited by 33
Hlavica, P. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-16009-2_10 · Cited by 33
Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy
Gong, L., Zhang, C., Lv, J., Zhou, H., & Fan, L. (2017) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000297 · Cited by 35
Papadakis, G. E., Dumont, A., Bouligand, J., Chasseloup, F., Raggi, A., Catteau-Jonard, S., Boute‐Bénéjean, O., Pitteloud, N., Young, J., & Dewailly, D. (2020) · Human Reproduction · doi:10.1093/humrep/deaa020 · Cited by 38
Moutinho, D., Marohnic, C. C., Panda, S. P., Rueff, J., Masters, B. S. S., & Kranendonk, M. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.042820 · Cited by 38
Modeling of human P450 oxidoreductase structure by in silico mutagenesis and MD simulation
Flück, C. E., Mullis, P. E., & Pandey, A. V. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2009.09.001 · Cited by 31
Self-citationPavithran, P. V., Ladjouze, A., Sauter, K., Pulickal, A., Katharopoulos, E., Trippel, M., Perren, A. A., Pandey, A. V., & Flück, C. E. (2020) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaa030 · Cited by 32
“Aromatase activity was then measured by the tritiated water release assay using cold/ hot androstenedione as substrate (10 nM/[1β-(3)H(N)]-androstene-3,17-dione; 20 000 cpm/well) as previously reported [1, 55].”
MethodSelf-citationHigh-Yield Expression of a Catalytically Active Membrane-Bound Protein: Human P450 Oxidoreductase
Sandee, D., & Miller, W. L. (2011) · Endocrinology · doi:10.1210/en.2011-0230 · Cited by 29
Miller, W. L. (2012) · Science Signaling · doi:10.1126/scisignal.2003318 · Cited by 36
Parween, S., Fernández-Cancio, M., Benito-Sanz, S., Camats, N., Rojas Velazquez, M. N., López-Siguero, J.-P., Udhane, S. S., Kagawa, N., Flück, C. E., Audí, L., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa076 · Cited by 28
Self-citationVelazquez, M. N. R., Parween, S., Udhane, S. S., & Pandey, A. V. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.05.127 · Cited by 31
Self-citationParween, S., Velazquez, M. N. R., Udhane, S. S., Kagawa, N., & Pandey, A. V. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01187 · Cited by 24
Self-citationZhao, C., Tang, T., Feng, X., & Qiu, L. (2013) · Pest Management Science · doi:10.1002/ps.3538 · Cited by 25
Ritacco, I., Spinello, A., Ippoliti, E., & Magistrato, A. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00157 · Cited by 26
Steroidogenic electron-transfer factors and their diseases
Miller, W. L. (2021) · Annals of Pediatric Endocrinology & Metabolism · doi:10.6065/apem.2142154.077 · Cited by 24
Song, T., Wang, B., Chen, H., Zhu, J., & Sun, H. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2017.1393663 · Cited by 24
Fan, L., Ren, X., Song, Y., Su, C., Fu, J., & Gong, C. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-1283-2 · Cited by 22
NADPH-cytochrome P450 reductase potentially involved in indoxacarb resistance in Spodoptera litura
Shi, L., Li, W., Dong, Y., Shi, Y., Zhou, Y., & Liao, X. (2021) · Pesticide Biochemistry and Physiology · doi:10.1016/j.pestbp.2021.104775 · Cited by 21
Pan, P., Zheng, L., Chen, X., Huang, J., Yang, D., & Li, Y. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00778-0 · Cited by 27
Bioactivity of curcumin on the cytochrome P450 enzymes of the steroidogenic pathwayPreprint
Castaño, P. R., Parween, S., & Pandey, A. V. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/669440 · Cited by 19
Self-citationHu, L., Pandey, A. V., Balmer, C., Eggimann, S., Rüfenacht, V., Nuoffer, J., & Häberle, J. (2015) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-014-9807-3 · Cited by 17
“…and hydrogen bonds, changes in charge, size and volume of the altered amino acid and interaction with neighbouring residues, to evaluate the impact of mutations as described previously for several other proteins and structures (Flück et al 2009; Pandey et al 2007; Pandey and Mullis 2011).”
BackgroundSelf-citationThe Adrenal Cortex and Its Disorders
Miller, W. L., Flück, C. E., Breault, D. T., & Feldman, B. J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-62520-3.00014-2 · Cited by 37
Self-citationVelazquez, M. N. R., Therkelsen, S., & Pandey, A. V. (2023) · Biomolecules · doi:10.3390/biom13121728 · Cited by 13
“The electron transfer from FMN further extends to its downstream redox partners, including various cytochrome P450 enzymes [28,29].”
BackgroundSelf-citationUnderestimated reactions and regulation patterns of adrenal cytochromes P450
Bernhardt, R., & Neunzig, J. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111237 · Cited by 14
Bioactivity of Curcumin on the Cytochrome P450 Enzymes of the Steroidogenic PathwayPreprint
Castaño, P. R., Parween, S., & Pandey, A. V. (2019) · Preprints.org · doi:10.20944/preprints201908.0102.v1 · Cited by 12
Self-citationRojas Velazquez, M. N., Noebauer, M., & Pandey, A. V. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710141 · Cited by 11
“Protein concentration was measured by Bradford [4,15,34,40].”
MethodSelf-citationUnal, E., Demiral, M., Yıldırım, R., Taş, F. F., Ceylaner, S., & Özbek, M. N. (2021) · Hormones · doi:10.1007/s42000-020-00249-z · Cited by 12
Delayed diagnosis of disorder of sex development (DSD) due to P450 oxidoreductase (POR) deficiency
Koika, V., Armeni, A. K., & Georgopoulos, N. A. (2016) · HORMONES · doi:10.14310/horm.2002.1679 · Cited by 14
Zhao, C., Feng, X., Tang, T., & Qiu, L. (2015) · Journal of Insect Science · doi:10.1093/jisesa/iev100 · Cited by 14
“At the C-terminus, the identified FAD and NADP binding domains are similar to those in human (H. sapiens), H. armigera and bed bug (Cimex lectularius) (Pandey et al. 2007; Zhu et al. 2012; Zhao et al. 2014).”
Wang, C., & Tian, Q. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1226387 · Cited by 11
Sarapusit, S., Pethuan, S., & Rongnoparut, P. (2010) · Archives of Insect Biochemistry and Physiology · doi:10.1002/arch.20354 · Cited by 12
“…mutations at the FAD-binding site have caused a total loss in CYP17A1 (17a-hydroxylase/17, 20-lyase) and CYP19A1 (aromatase) activities and impaired the drug-metabolizing CYP1A2 enzyme activity in vitro (Marochic et al., 2006; Flúck et al., 2007; Pandey et al., 2007; Kranendonk et al., 2008).”
BackgroundSarapusit, S., Lertkiatmongkol, P., Duangkaew, P., & Rongnoparut, P. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14011788 · Cited by 11
Inaoka, Y., Yazawa, T., Mizutani, T., Kokame, K., Kangawa, K., Uesaka, M., Umezawa, A., & Miyamoto, K. (2008) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-6-62 · Cited by 10
Ibrahim, S. S., Kouamo, M., Muhammad, A., Irving, H., Riveron, J. M., Tchouakui, M., & Wondji, C. S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25158092 · Cited by 13
“For example, in humans, CPR is involved in steroidogenesis, bone formation, and drug metabolism [48], and mutations in the human CPR result in reduced activities of steroid metabolising enzymes, CYP17A1 (17, α -hydroxylase)/17,20 lyase), and CYP19A1 (aromatase), causing a rare form of congenital…”
BackgroundCYP4G7 and CYP4G14 mediate cuticle formation and pigmentation in Tribolium confusum
Huang, Y., Shi, S., Wu, H., Yue, S., Liao, M., & Cao, H. (2021) · Journal of Stored Products Research · doi:10.1016/j.jspr.2021.101881 · Cited by 12
Theoretical Study of the Mechanism of Exemestane Hydroxylation Catalyzed by Human Aromatase Enzyme
Viciano, I., & Martí, S. (2016) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.6b01014 · Cited by 11
P450 Oxidoreductase Deficiency (PORD)
Flück, C. E., & Pandey, A. V. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00010-7 · Cited by 11
Self-citationHuman P450 Oxidoreductase Deficiency
Flück, C. E., & Pandey, A. V. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.64966-8 · Cited by 12
Self-citationDiagnosis and Treatment of Disorders of Sexual Development
Rey, R. A., Josso, N., & Forest, M. G. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5583-9.00119-2 · Cited by 6
Flück, C. E., & Pandey, A. V. (2017) · Endocrinology · doi:10.1007/978-3-319-44441-3_10 · Cited by 17
Self-citation
Metadata
- Authors
- Pandey, A. V., Kempná, P., Hofer, G., Mullis, P. E., & Flück, C. E.
- Affiliations
- University of Bern (CH)
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-10
- Volume
- 21
- Issue
- 10
- Pages
- 2579-2595
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2045490130
- Semantic Scholar
- 250e545e90127942a775447e5f4c518fe09840aa
- Cited by
- 132
- References
- 90
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 8 · 2019: 13 · 2018: 4 · 2017: 9 · 2016: 9 · 2015: 9 · 2014: 6 · 2013: 7 · 2012: 8
- FWCI
- 7.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Molecular Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion)
- Funders
- Sichuan University of Science and Engineering
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- CYP19A1, aromatase, steroidogenesis, FAD domain, electron transfer, NADH, pH effect, 1-octanol, enzyme kinetics
- MeSH terms
- Aromatase, Binding Sites, Electron Transport, Humans, Hydrogen-Ion Concentration, Models, Molecular, Mutation, NADPH-Ferrihemoprotein Reductase, Potassium Chloride, Steroid 17-alpha-Hydroxylase, Protein Structure, Tertiary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.